India, Aug. 26 -- Curanex Pharmaceuticals Inc. (CURX) Tuesday said it has priced its initial public offering of 3.75 million shares at $4 per share.
The company's shares will start trading on the Nasdaq on August 26 under the ticker CURX.
Curanex intends to use the net proceeds from the offering of $15 million to develop its lead product candidate, Phyto-N, for the treatment of ulcerative colitis; to conduct FDA-required good laboratory practice (GLP) toxicology and pharmacokinetic studies for Phyto-N in ulcerative colitis; to prepare and submit an Investigational New Drug (IND) application; and for working capital and other general corporate purposes.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
...